Pharming (PHAR) Non Operating Interest Expenses (2020 - 2023)
Pharming's (PHAR) quarterly Non Operating Interest Expenses came in at -$633000.0 in Q3 2023, down 152.84% YoY from $1.2 million in Q3 2022, and down 152.84% on a QoQ basis from $1.2 million in Q3 2022.
Pharming (PHAR) Non Operating Interest Expenses (2020 - 2023) Analysis & Trends
Pharming (PHAR) has 4 years of Non Operating Interest Expenses data on file, last reported at -$633000.0 in Q3 2023.
- Quarterly Non Operating Interest Expenses fell 152.84% year-over-year to -$633000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $3.1 million (down 17.77% YoY) and the FY2021 annual result came in at $8511.1, up 126.19% from the prior year.
- Non Operating Interest Expenses retreated to -$633000.0 in Q3 2023, from $1.2 million in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $12.3 million in Q3 2020 to a low of -$633000.0 in Q3 2023.
- A 4-year average of $2.6 million and a median of $616378.2 in 2022 frame the typical range for Non Operating Interest Expenses.
- Annual changes were most pronounced in 2022 — Non Operating Interest Expenses sank 52.44% — and 2023, when it tumbled 152.84%.
- Tracing PHAR's Non Operating Interest Expenses over 4 years: stood at $34756.4 in 2020, then sank by 82.8% to $5977.2 in 2021, then jumped by 19942.67% to $1.2 million in 2022, then plunged by 152.84% to -$633000.0 in 2023.
- The last three Non Operating Interest Expenses figures came in at -$633000.0 (Q3 2023), $1.2 million (Q3 2022), and $5977.2 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -633,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Dec 31, 2021 | 5,977.25 |
| Sep 30, 2021 | 2.52 Mn |
| Dec 31, 2020 | 34,756.44 |
| Sep 30, 2020 | 12.32 Mn |